Compared with the unmodified PROTAC 17, the designed molecule PROTAC 19 (Figure 8) showed improved tumour targeting ability in a MCF-7 xenograft model, leading to enhanced in vivo BET degradation and antitumor potency and decreased toxicity. The gene discussed is DNER; the disease is neoplasm.